Cited by 121Animal testing and alternativesCancer Cells and MetastasisScience, Research, and Medicine

The DOI matches its Crossref record; 163 of the 166 references it cites were found in a registry or an index.

Harnessing the predictive power of preclinical models for oncology drug development

Honkala, Alexander, Malhotra, Sanjay V., Kummar, Shivaani, Junttila, Melissa R.·2022·Nature Reviews Drug Discovery

Open this paper in CoChat — free account

Abstract

Recent progress in understanding the molecular basis of cellular processes, identification of promising therapeutic targets and evolution of the regulatory landscape makes this an exciting and unprecedented time to be in the field of oncology drug development. However, high costs, long development timelines and steep rates of attrition continue to afflict the drug development process. Lack of predictive preclinical models is considered one of the key reasons for the high rate of attrition in oncology. Generating meaningful and predictive results preclinically requires a firm grasp of the relevant biological questions and alignment of the model systems that mirror the patient context. In doing so, the ability to conduct both forward translation, the process of implementing basic research discoveries into practice, as well as reverse translation, the process of elucidating the mechanistic basis of clinical observations, greatly enhances our ability to develop effective anticancer treatments. In this Review, we outline issues in preclinical-to-clinical translatability of molecularly targeted cancer therapies, present concepts and examples of successful reverse translation, and highlight the need to better align tumour biology in patients with preclinical model systems including tracking of strengths and weaknesses of preclinical models throughout programme development.

Integrity signals

Registry

Crossref · 10.1038/s41573-021-00301-6

Cites

163 of 163 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Double-slit photoelectron interference in strong-field ionization of the neon dimer
Kunitski, M., Eicke, N., Huber, P., Köhler, J., Zeller, S., Voigtsberger, J., Schlott, N., Henrichs, K., Sann, H., Trinter, F., et al. (2019) · Institutional Repository of Leibniz Universität Hannover (Leibniz Universität Hannover) · doi:10.15488/5174 · Cited by 8,378
Double-slit photoelectron interference in strong-field ionization of the neon dimer
Kunitski, M., Eicke, N., Huber, P., Köhler, J., Zeller, S., Voigtsberger, J., Schlott, N., Henrichs, K., Sann, H., Trinter, F., et al. (2019) · Nature Communications · doi:10.1038/s41467-018-07882-8 · Cited by 8,162
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer
Soria, J.-C., Ohe, Y., Vansteenkiste, J., Reungwetwattana, T., Chewaskulyong, B., Lee, K. H., Dechaphunkul, A., Imamura, F., Nogami, N., Kurata, T., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1713137 · Cited by 5,508
Cancer drug resistance: an evolving paradigm
Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3599 · Cited by 4,681
EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338
Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells
Yang, W., Soares, J., Greninger, P., Edelman, E. J., Lightfoot, H., Forbes, S., Bindal, N., Beare, D., Smith, J. A., Thompson, I. R., et al. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks1111 · Cited by 4,051
Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain
Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527
Defining a Cancer Dependency Map
Tsherniak, A., Vazquez, F., Montgomery, P. G., Weir, B. A., Kryukov, G., Cowley, G. S., Gill, S., Harrington, W. F., Pantel, S., Krill-Burger, J. M., et al. (2017) · Cell · doi:10.1016/j.cell.2017.06.010 · Cited by 3,276
Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer
Olive, K. P., Jacobetz, M. A., Davidson, C. J., Gopinathan, A., McIntyre, D., Honess, D., Madhu, B., Goldgraben, M. A., Caldwell, M. E., Allard, D., et al. (2009) · Science · doi:10.1126/science.1171362 · Cited by 3,170
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Flaherty, K. T., Puzanov, I., Kim, K. B., Ribas, A., McArthur, G. A., Sosman, J. A., O'Dwyer, P. J., Lee, R. J., Grippo, J. F., Nolop, K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002011 · Cited by 3,103
Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF
Wan, P., Garnett, M. J., Roe, S. M., Lee, S., Niculescu‐Duvaz, D., Good, V. M., Cancer Genome Project, Jones, C. M., Marshall, C. J., Springer, C. J., et al. (2004) · Cell · doi:10.1016/s0092-8674(04)00215-6 · Cited by 2,863
Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
Drilon, A., Laetsch, T. W., Kummar, S., DuBois, S. G., Lassen, U. N., Demetri, G. D., Nathenson, M., Doebele, R. C., Farago, A. F., Pappo, A. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714448 · Cited by 2,824
Self-citation
Systematic identification of genomic markers of drug sensitivity in cancer cells
Garnett, M. J., Edelman, E. J., Heidorn, S. J., Greenman, C. D., Dastur, A., Lau, K. W., Greninger, P., Thompson, I. R., Luo, X., Soares, J., et al. (2012) · Nature · doi:10.1038/nature11005 · Cited by 2,456
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
Nazarian, R., Shi, H., Wang, Q., Kong, X., Koya, R. C., Lee, H., Chen, Z., Lee, M., Attar, N., Sazegar, H., et al. (2010) · Nature · doi:10.1038/nature09626 · Cited by 2,244
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib
Sosman, J. A., Kim, K. B., Schuchter, L., Gonzalez, R., Pavlick, A. C., Weber, J. S., McArthur, G. A., Hutson, T. E., Moschos, S. J., Flaherty, K. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112302 · Cited by 2,156
Combined Vemurafenib and Cobimetinib in BRAF -Mutated Melanoma
Larkin, J., Ascierto, P. A., Dréno, B., Atkinson, V. G., Liszkay, G., Maio, M., Mandalà, M., Демидов, Л. В., Stroyakovskiy, D., Thomas, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408868 · Cited by 2,115
Patient-derived organoids model treatment response of metastatic gastrointestinal cancers
Vlachogiannis, G., Hedayat, S., Vatsiou, A., Jamin, Y., Fernández-Mateos, J., Khan, K., Lampis, A., Eason, K., Huntingford, I., Burke, R., et al. (2018) · Science · doi:10.1126/science.aao2774 · Cited by 2,096
Stromal Elements Act to Restrain, Rather Than Support, Pancreatic Ductal Adenocarcinoma
Rhim, A. D., Oberstein, P. E., Thomas, D. H., Mirek, E. T., Palermo, C. F., Sastra, S. A., Dekleva, E. N., Saunders, T., Becerra, C. P., Tattersall, I. W., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.04.021 · Cited by 2,085
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Prahallad, A., Sun, C., Huang, S., Di Nicolantonio, F., Salazar, R., Zecchin, D., Beijersbergen, R. L., Bardelli, A., & Bernards, R. (2012) · Nature · doi:10.1038/nature10868 · Cited by 2,051
Diagnosing the decline in pharmaceutical R&D efficiency
Scannell, J. W., Blanckley, A., Boldon, H., & Warrington, B. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3681 · Cited by 1,981
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
Poulikakos, P. I., Zhang, C., Bollag, G. E., Shokat, K. M., & Rosen, N. X. (2010) · Nature · doi:10.1038/nature08902 · Cited by 1,841
Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research
Hidalgo, M. M., Amant, F. C., Biankin, A. V., Budínská, E., Byrne, A. T., Caldas, C., Clarke, R. B., de Jong, S., Jonkers, J., Mælandsmo, G. M., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0001 · Cited by 1,797
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
Hyman, D. M., Puzanov, I., Subbiah, V., Faris, J. E., Chau, I., Blay, J.-Y., Wolf, J., Raje, N. S., Diamond, E. L., Hollebecque, A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1502309 · Cited by 1,764
Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1
Giaccone, G., Herbst, R. S., Manegold, C., Scagliotti, G. V., Rosell, R., Miller, V. A., Natale, R. B., Schiller, J. H., von Pawel, J., Pluzanska, A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.001 · Cited by 1,712
Gefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 2
Herbst, R. S., Giaccone, G., Schiller, J. H., Natale, R. B., Miller, V. A., Manegold, C., Scagliotti, G. V., Rosell, R., Oliff, I. A., Reeves, J. A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.07.215 · Cited by 1,701
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
Hatzivassiliou, G., Song, K. W., Yen, I., Brandhuber, B. J., Anderson, D. J., Alvarado, R., Ludlam, M. J. C., Stokoe, D., Gloor, S. L., Vigers, G. P. A., et al. (2010) · Nature · doi:10.1038/nature08833 · Cited by 1,649
Estimation of clinical trial success rates and related parameters
Wong, C. H., Siah, K. W., & Lo, A. W. (2019) · Biostatistics · doi:10.1093/biostatistics/kxx069 · Cited by 1,585
Organoid modeling of the tumor immune microenvironment
Neal, J. T., Li, X., Zhu, J., Giangarra, V., Grzeskowiak, C. L., Ju, J., Liu, I. H., Chiou, S.-H., Salahudeen, A. A., Smith, A. R., et al. (2018) · Cell · doi:10.1016/j.cell.2018.11.021 · Cited by 1,556
Adjuvant Dabrafenib plus Trametinib in Stage III BRAF -Mutated Melanoma
Long, G. V., Hauschild, A., Santinami, M., Atkinson, V. G., Mandalà, M., Chiarion‐Sileni, V., Larkin, J., Nyakas, M., Dutriaux, C., Haydon, A. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708539 · Cited by 1,538
Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
Heidorn, S. J., Milagre, C. S., Whittaker, S. R., Nourry, A., Niculescu‐Duvaz, I., Dhomen, N. S., Hussain, J., Reis-Filho, J. S., Springer, C. J., Pritchard, C. A., et al. (2010) · Cell · doi:10.1016/j.cell.2009.12.040 · Cited by 1,497
Human primary liver cancer–derived organoid cultures for disease modeling and drug screening
Broutier, L., Mastrogiovanni, G., Verstegen, M. M., Francies, H. E., Gavarró, L. M., Bradshaw, C. R., Allen, G. E., Arnes-Benito, R., Sidorova, O., Gaspersz, M. P., et al. (2017) · Nature Medicine · doi:10.1038/nm.4438 · Cited by 1,471
Evaluating cell lines as tumour models by comparison of genomic profiles
Domcke, S., Sinha, R., Levine, D. A., Sander, C., & Schultz, N. D. (2013) · Nature Communications · doi:10.1038/ncomms3126 · Cited by 1,457
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
Poulikakos, P. I., Persaud, Y., Janakiraman, M., Kong, X., Ng, C., Moriceau, G., Shi, H., Atefi, M., Titz, B., Gabay, M. T., et al. (2011) · Nature · doi:10.1038/nature10662 · Cited by 1,454
Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer
Leonetti, A., Sharma, S., Minari, R., Perego, P., Giovannetti, E., & Tiseo, M. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0573-8 · Cited by 1,448
High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response
Gao, H., Korn, J. M., Ferretti, S., Monahan, J. E., Wang, Y., Singh, M., Zhang, C., Schnell, C., Yang, G., Zhang, Y., et al. (2015) · Nature Medicine · doi:10.1038/nm.3954 · Cited by 1,393
Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K
Villanueva, J., Vultur, A., Lee, J. T., Somasundaram, R., Fukunaga‐Kalabis, M., Cipolla, A. K., Wubbenhorst, B. S., Xu, X., Gimotty, P. A., Kee, D., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.11.023 · Cited by 1,289
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial
Wu, Y.-L., Cheng, Y., Zhou, X., Lee, K. H., Nakagawa, K., Niho, S., Tsuji, F., Linke, R., Rosell, R., Corral, J., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30608-3 · Cited by 1,216
RAS Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors
Su, F., Virós, A., Milagre, C. S., Trunzer, K., Bollag, G. E., Spleiss, O., Reis-Filho, J. S., Kong, X., Koya, R. C., Flaherty, K. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1105358 · Cited by 1,056
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial
Dummer, R., Ascierto, P. A., Gogas, H. J., Arance, A. M., Mandalà, M., Liszkay, G., Garbe, C., Schadendorf, D., Krajsová, I., Gutzmer, R., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30142-6 · Cited by 1,034
Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling
Wagle, N., Emery, C., Berger, M. F., Davis, M. J., Sawyer, A. M., Pochanard, P., Kehoe, S. M., Johannessen, C. M., MacConaill, L. E., Hahn, W. C., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.2312 · Cited by 1,028
Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes
DeRose, Y. S., Wang, G., Lin, Y.-C., Bernard, P. S., Buys, S. S., Ebbert, M., Factor, R. E., Matsen, C. B., Milash, B. A., Nelson, E. W., et al. (2011) · Nature Medicine · doi:10.1038/nm.2454 · Cited by 1,025
EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of BRAF -Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib
Corcoran, R. B., Ebi, H., Turke, A. B., Coffee, E. M., Nishino, M., Cogdill, A. P., Brown, R. D., Della Pelle, P., Dias-Santagata, D., Hung, K. E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0341 · Cited by 1,022
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial
Sartore-Bianchi, A., Trusolino, L., Martino, C., Bencardino, K., Lonardi, S., Bergamo, F., Zagonel, V., Leone, F., Depetris, I., Martinelli, E., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00150-9 · Cited by 1,016
Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition
Hata, A. N., Niederst, M. J., Archibald, H. L., Gomez-Caraballo, M., Siddiqui, F. M., Mulvey, H. E., Maruvka, Y. E., Ji, F., Bhang, H.-E. C., Krishnamurthy Radhakrishna, V., et al. (2016) · Nature Medicine · doi:10.1038/nm.4040 · Cited by 985
Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy
Shi, H., Hugo, W., Kong, X., Hong, A., Koya, R. C., Moriceau, G., Chodon, T., Guo, R., Johnson, D. B., Dahlman, K. B., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0642 · Cited by 982
A molecularly annotated platform of patient-derived xenografts (“xenopatients”) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer
Bertotti, A., Migliardi, G., Galimi, F., Sassi, F., Torti, D., Isella, C., Corà, D., Di Nicolantonio, F., Buscarino, M., Petti, C., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0109 · Cited by 939
Cancer modeling meets human organoid technology
Tuveson, D., & Clevers, H. (2019) · Science · doi:10.1126/science.aaw6985 · Cited by 935
Genetic and transcriptional evolution alters cancer cell line drug response
Ben-David, U., Siranosian, B., Ha, G., Tang, H., Oren, Y., Hinohara, K., Strathdee, C. A., Dempster, J., Lyons, N. J., Burns, R., et al. (2018) · Nature · doi:10.1038/s41586-018-0409-3 · Cited by 931
Carcinogen-specific mutation and amplification of Ha-ras during mouse skin carcinogenesis
Quintanilla, M., Brown, K., Ramsden, M., & Balmain, A. (1986) · Nature · doi:10.1038/322078a0 · Cited by 852
A distinct role for Lgr5+ stem cells in primary and metastatic colon cancer
Melo, F. D. S. E., Kurtova, A. V., Harnoss, J. M., Kljavin, N. M., Hoeck, J. D., Hung, J., Anderson, J. E., Storm, E. E., Modrusan, Z. D., Koeppen, H., et al. (2017) · Nature · doi:10.1038/nature21713 · Cited by 812
The great escape: tumour cell plasticity in resistance to targeted therapy
Boumahdi, S., & de Sauvage, F. J. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0044-1 · Cited by 785
Patient-derived xenografts undergo mouse-specific tumor evolution
Ben-David, U., Ha, G., Tseng, Y.-Y., Greenwald, N. F., Oh, C., Shih, J., McFarland, J. M., Wong, B., Boehm, J. S., Beroukhim, R., et al. (2017) · Nature Genetics · doi:10.1038/ng.3967 · Cited by 716
Patient-derived models of acquired resistance can identify effective drug combinations for cancer
Crystal, A. S., Shaw, A. T., Sequist, L. V., Friboulet, L., Niederst, M. J., Lockerman, E. L., Frias, R. L., Gainor, J. F., Amzallag, A., Greninger, P., et al. (2014) · Science · doi:10.1126/science.1254721 · Cited by 708
Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF -Mutated Colorectal Cancer
Kopetz, S., Desai, J., Chan, E., Hecht, J. R., O'Dwyer, P. J., Maru, D., Morris, V., Janku, F., Dasari, A., Chung, W., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.2497 · Cited by 697
Oncogenic Transformation by Inhibitor-Sensitive and -Resistant EGFR Mutants
Greulich, H., Chen, T.-H., Feng, W., Jänne, P. A., Alvarez, J. V., Zappaterra, M., Bulmer, S. E., Frank, D. A., Hahn, W. C., Sellers, W. R., et al. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020313 · Cited by 677
Project DRIVE: a compendium of cancer dependencies and synthetic lethal relationships uncovered by large-scale, deep RNAi screening
McDonald, E. R., de Weck, A., Schlabach, M. R., Billy, E., Mavrakis, K. J., Hoffman, G. R., Belur, D., Castelletti, D., Frias, E., Gampa, K., et al. (2017) · Cell · doi:10.1016/j.cell.2017.07.005 · Cited by 658
MEK1 mutations confer resistance to MEK and B-RAF inhibition
Emery, C. M., Vijayendran, K. G., Zipser, M. C., Sawyer, A. M., Niu, L., Kim, J. J., Hatton, C., Chopra, R., Oberholzer, P. A., Karpova, M. B., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905833106 · Cited by 656
Oncogenic Braf Induces Melanocyte Senescence and Melanoma in Mice
Dhomen, N. S., Reis-Filho, J. S., Dias, S. D. R., Hayward, R., Savage, K., Delmas, V., Larue, L., Pritchard, C. A., & Marais, R. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.02.022 · Cited by 626
Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAF V600E-Mutant Colorectal Cancer
Corcoran, R. B., André, T., Atreya, C. E., Schellens, J. H. M., Yoshino, T., Bendell, J. C., Hollebecque, A., McRee, A. J., Siena, S., Middleton, G., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1226 · Cited by 592
Randomized phase Ib/II study of gemcitabine plus placebo or vismodegib, a hedgehog pathway inhibitor, in patients with metastatic pancreatic cancer
Catenacci, D. V. T., Junttila, M. R., Karrison, T., Bahary, N., Horiba, M. N., Nattam, S. R., Marsh, R., Wallace, J., Kozloff, M., Rajdev, L., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.8719 · Cited by 561
Self-citation
Correction: Corrigendum: ER-localized auxin transporter PIN8 regulates auxin homoeostasis and male gametophyte development in Arabidopsis
Ding, Z., Wang, B., Moreno, I., Dupľáková, N., Simon, S., Carraro, N., Reemmer, J., Pěnčík, A., Chen, X., Tejos, R., et al. (2013) · Nature Communications · doi:10.1038/ncomms2452 · Cited by 555
Genetically engineered mouse models in oncology research and cancer medicine
Kersten, K., de Visser, K. E., van Miltenburg, M. H., & Jonkers, J. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201606857 · Cited by 502
Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials
Schwaederle, M. C., Zhao, M. M., Lee, J. J., Eggermont, A. M. M., Schilsky, R. L., Mendelsohn, J. M., Lazar, V., & Kurzrock, R. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.61.5997 · Cited by 495
A new mouse model to explore the initiation, progression, and therapy of BRAF V600E -induced lung tumorsPreprint
Dankort, D. L., Filenova, E., Collado, M., Serrano, M., Jones, K. D., & McMahon, M. (2007) · Genes & Development · doi:10.1101/gad.1516407 · Cited by 492
Lung adenocarcinomas induced in mice by mutant EGF receptors foundin human lung cancers respondto a tyrosine kinase inhibitor orto down-regulation of the receptors
Politi, K., Zakowski, M. F., Fan, P.-D., Schonfeld, E. A., Pao, W., & Varmus, H. E. (2006) · Genes & Development · doi:10.1101/gad.1417406 · Cited by 478
The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies
Ji, H., Li, D., Chen, L., Shimamura, T., Kobayashi, S., McNamara, K., Mahmood, U., Mitchell, A., Sun, Y., Al-Hashem, R., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.04.022 · Cited by 462
Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR -Mutant Lung Cancer
Schoenfeld, A. J., Chan, J. M., Kubota, D., Sato, H., Rizvi, H., Daneshbod, Y., Chang, J. C., Paik, P. K., Offin, M., Arcila, M. E., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3563 · Cited by 411
Development of primary human pancreatic cancer organoids, matched stromal and immune cells and 3D tumor microenvironment models
Tsai, S., McOlash, L., Palen, K., Johnson, B., Duris, C., Yang, Q., Dwinell, M. B., Hunt, B., Evans, D. B., Gershan, J., et al. (2018) · BMC Cancer · doi:10.1186/s12885-018-4238-4 · Cited by 400
RAS Mutations Are Associated With the Development of Cutaneous Squamous Cell Tumors in Patients Treated With RAF Inhibitors
Oberholzer, P. A., Kee, D., Dziunycz, P., Sucker, A., Kamsu-Kom, N., Jones, R. T., Roden, C., Chalk, C. J., Ardlie, K., Palescandolo, E., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.7680 · Cited by 386
Resistance to BRAF-targeted therapy in melanoma
Sullivan, R. J., & Flaherty, K. T. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2012.11.019 · Cited by 386
Estimation of the Percentage of US Patients With Cancer Who Benefit From Genome-Driven Oncology
Marquart, J. P., Chen, E. Y.-S., & Prasad, V. K. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.1660 · Cited by 386
Examining the utility of patient-derived xenograft mouse models
Aparicio, S. A. J. R., Hidalgo, M. M., & Kung, A. L. (2015) · Nature reviews. Cancer · doi:10.1038/nrc3944 · Cited by 352
Tunable-Combinatorial Mechanisms of Acquired Resistance Limit the Efficacy of BRAF/MEK Cotargeting but Result in Melanoma Drug Addiction
Moriceau, G., Hugo, W., Hong, A., Shi, H., Kong, X., Yu, C. C., Koya, R. C., Samatar, A. A., Khanlou, N., Braun, J. G., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2014.11.018 · Cited by 351
Afatinib: First Global Approval
Dungo, R. T., & Keating, G. M. (2013) · Drugs · doi:10.1007/s40265-013-0111-6 · Cited by 344
The mutational landscapes of genetic and chemical models of Kras-driven lung cancer
Westcott, P. M. K., Halliwill, K. D., To, M. D., Rashid, M., Rust, A. G., Keane, T., Delrosario, R., Jen, K., Gurley, K. E., Kemp, C. J., et al. (2014) · Nature · doi:10.1038/nature13898 · Cited by 338
Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms
Johnson, D. B., Menzies, A. M., Zimmer, L., Eroglu, Z., Ye, F., Zhao, S., Rizos, H., Sucker, A., Scolyer, R. A., Gutzmer, R., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.08.022 · Cited by 331
The Generation and Application of Patient-Derived Xenograft Model for Cancer Research
Jung, J., Seol, H. S., & Chang, S. (2017) · Cancer Research and Treatment · doi:10.4143/crt.2017.307 · Cited by 325
Translational value of mouse models in oncology drug development
Gould, S. E., Junttila, M. R., & de Sauvage, F. J. (2015) · Nature Medicine · doi:10.1038/nm.3853 · Cited by 293
Self-citation
Organoid cultures from normal and cancer-prone human breast tissues preserve complex epithelial lineages
Rosenbluth, J. M., Schackmann, R. C. J., Gray, G. K., Selfors, L. M., Li, C. M.-C., Boedicker, M., Kuiken, H. J., Richardson, A. L., Brock, J. E., Garber, J. E., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15548-7 · Cited by 277
Application of Highly Immunocompromised Mice for the Establishment of Patient-Derived Xenograft (PDX) Models
Okada, S., Vaeteewoottacharn, K., & Kariya, R. (2019) · Cells · doi:10.3390/cells8080889 · Cited by 264
The Hedgehog Signaling Pathway in Cancer
Evangelista, M., Tian, H., & de Sauvage, F. J. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1736 · Cited by 251
Transplantation of engineered organoids enables rapid generation of metastatic mouse models of colorectal cancer
O’Rourke, K. P., Loizou, E., Livshits, G., Schatoff, E. M., Baslan, T., Manchado, E., Simon, J. M., Romesser, P. B., Leach, B. I., Han, T., et al. (2017) · Nature Biotechnology · doi:10.1038/nbt.3837 · Cited by 244
Mapping Optogenetically Driven Single-Vessel fMRI with Concurrent Neuronal Calcium Recordings in the Rat Hippocampus
Chen, X., Sobczak, F., Chen, Y., Jiang, Y., Qian, C., Lu, Z., Ayata, C., Logothetis, N. K., & Yu, X. (2019) · Nature Communications · doi:10.1038/s41467-019-12850-x · Cited by 242
Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and management
Heinzerling, L., Eigentler, T., Fluck, M., Hassel, J. C., Heller-Schenck, D., Leipe, J., Pauschinger, M., Vogel, A., Zimmer, L., & Gutzmer, R. (2019) · ESMO Open · doi:10.1136/esmoopen-2019-000491 · Cited by 242
Oncogenic BRAF Is Required for Tumor Growth and Maintenance in Melanoma Models
Hoeflich, K. P., Gray, D. C., Eby, M. T., Tien, J., Wong, L. L.-Y., Bower, J., Gogineni, A., Zha, J., Cole, M. J., Stern, H. M., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2720 · Cited by 234
Genomic evolution of cancer models: perils and opportunities
Ben‐David, U., Beroukhim, R., & Golub, T. R. (2018) · Nature reviews. Cancer · doi:10.1038/s41568-018-0095-3 · Cited by 234
Patient-derived explants (PDEs) as a powerful preclinical platform for anti-cancer drug and biomarker discovery
Powley, I. R., Patel, M., Miles, G. J., Pringle, H., Howells, L. M., Thomas, A., Kettleborough, C. A., Bryans, J. S., Hammonds, T. R., MacFarlane, M., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-019-0672-6 · Cited by 230
Emerging organoid models: leaping forward in cancer research
Fan, H., Demirci, U., & Chen, P. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0832-4 · Cited by 199
CRISPR/Cas9 somatic multiplex-mutagenesis for high-throughput functional cancer genomics in mice
Weber, J., Öllinger, R., Friedrich, M., Ehmer, U., Barenboim, M., Steiger, K., Heid, I., Mueller, S., Maresch, R., Engleitner, T., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1512392112 · Cited by 195
Emergence of Epidermal Growth Factor Receptor T790M Mutation during Chronic Exposure to Gefitinib in a Non–Small Cell Lung Cancer Cell Line
Ogino, A., Kitao, H., Hirano, S., Uchida, A., Ishiai, M., Kozuki, T., Takigawa, N., Takata, M., Kiura, K., & Tanimoto, M. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0681 · Cited by 194
Mutational landscape of EGFR- , MYC- , and Kras- driven genetically engineered mouse models of lung adenocarcinoma
McFadden, D. G., Politi, K., Bhutkar, A., Chen, F. K., Song, X., Pirun, M., Santiago, P. M., Kim-Kiselak, C., Platt, J. T., Lee, E., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1613601113 · Cited by 194
Comparison of the molecular and cellular phenotypes of common mouse syngeneic models with human tumors
Zhong, W., Myers, J. S., Wang, F., Wang, K., Lucas, J., Rosfjord, E. C., Lucas, J., Hooper, A. T., Yang, S., Lemon, L., et al. (2020) · BMC Genomics · doi:10.1186/s12864-019-6344-3 · Cited by 194
Syngeneic mouse mammary carcinoma cell lines: Two closely related cell lines with divergent metastatic behavior
Borowsky, A. D., Namba, R., Young, L. J. T., Hunter, K. W., Hodgson, J., Tepper, C. G., McGoldrick, E. T., Muller, W. J., Cardiff, R. D., & Gregg, J. P. (2005) · Clinical & Experimental Metastasis · doi:10.1007/s10585-005-2908-5 · Cited by 190
Resistance to Selective BRAF Inhibition Can Be Mediated by Modest Upstream Pathway Activation
Su, F., Bradley, W. D., Wang, Q., Yang, H. Y., Xu, L., Higgins, B., Kolinsky, K. D., Packman, K. E., Kim, M. J., Trunzer, K., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1875 · Cited by 180
Phase 2 study of vismodegib, a hedgehog inhibitor, combined with gemcitabine and nab-paclitaxel in patients with untreated metastatic pancreatic adenocarcinoma
Jesus‐Acosta, A. D., Sugar, E. A., O'Dwyer, P. J., Ramanathan, R. K., Hoff, D. D. V., Rasheed, Z. A., Zheng, L., Begum, A., Anders, R. A., Maitra, A., et al. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0683-3 · Cited by 178
Mutations in BRAF and KRAS Converge on Activation of the Mitogen-Activated Protein Kinase Pathway in Lung Cancer Mouse Models
Ji, H., Wang, Z., Perera, S. A., Li, D., Liang, M., Zaghlul, S., McNamara, K. L., Chen, L., Albert, M., Sun, Y., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4592 · Cited by 176
CRISPR-Cas9–mediated gene knockout in intestinal tumor organoids provides functional validation for colorectal cancer driver genes
Takeda, H., Kataoka, S., Nakayama, M., Ali, M. A. E., Oshima, H., Yamamoto, D., Park, J.-W., Takegami, Y., An, T., Jenkins, N. A., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1904714116 · Cited by 172
The organoid cell atlas
the Human Cell Atlas ‘Biological Network’ Organoids, Bock, C., Boutros, M., Camp, J. G., Clarke, L., Clevers, H., Knoblich, J. A., Liberali, P., Regev, A., Rios, A. C., et al. (2021) · Nature Biotechnology · doi:10.1038/s41587-020-00762-x · Cited by 171
Comprehensive transcriptomic analysis of cell lines as models of primary tumors across 22 tumor types
Yu, K., Chen, B., Aran, D., Charalel, J. K., Yau, C. S. F., Wolf, D. M., Veer, L. V. ‘., Butte, A. J., Goldstein, T. C., & Sirota, M. (2019) · Nature Communications · doi:10.1038/s41467-019-11415-2 · Cited by 165
Efficient Use of Patient-Derived Organoids as a Preclinical Model for Gynecologic Tumors
Maru, Y., Tanaka, N., Itami, M., & Hippo, Y. (2019) · Gynecologic Oncology · doi:10.1016/j.ygyno.2019.05.005 · Cited by 162
Patient‐derived xenografts for individualized care in advanced sarcoma
Stebbing, J., Paz, K., Schwartz, G. K., Wexler, L. H., Maki, R. G., Pollock, R. E., Morris, R., Cohen, R., Shankar, A., Blackman, G., et al. (2014) · Cancer · doi:10.1002/cncr.28696 · Cited by 157
A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma
Krepler, C., Sproesser, K., Brafford, P. A., Beqiri, M., Garman, B., Xiao, M., Shannan, B., Watters, A. K., Perego, M., Zhang, G., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.10.021 · Cited by 152
The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models
Katayama, R., Gong, B., Togashi, N., Miyamoto, M., Kiga, M., Iwasaki, S., Kamai, Y., Tominaga, Y., Takeda, Y., Kagoshima, Y., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11496-z · Cited by 148
CRISPR/Cas9 mutagenesis invalidates a putative cancer dependency targeted in on-going clinical trials
Lin, A., Giuliano, C. J., Sayles, N. M., & Sheltzer, J. M. (2017) · eLife · doi:10.7554/elife.24179 · Cited by 147
Physiologically Based Pharmacokinetic Modelling for First-In-Human Predictions: An Updated Model Building Strategy Illustrated with Challenging Industry Case Studies
Miller, N. A., Reddy, M. B., Heikkinen, A. T., Lukacova, V., & Parrott, N. (2019) · Clinical Pharmacokinetics · doi:10.1007/s40262-019-00741-9 · Cited by 142
Exploiting evolutionary steering to induce collateral drug sensitivity in cancer
Acar, A., Nichol, D., Fernández-Mateos, J., Cresswell, G. D., Barozzi, I., Hong, S. P., Trahearn, N., Spiteri, I., Stubbs, M., Burke, R., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15596-z · Cited by 137
Antitumor activity of targeted and cytotoxic agents in murine subcutaneous tumor models correlates with clinical response
Wong, H., Choo, E. F., Alicke, B., Ding, X., La, H., McNamara, E., Theil, F.-P., Tibbitts, J., Friedman, L. S., Hop, C. E. C. A., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0738 · Cited by 133
Development of New Mouse Lung Tumor Models Expressing EGFR T790M Mutants Associated with Clinical Resistance to Kinase Inhibitors
Regales, L., Balak, M. N., Gong, Y., Politi, K. A., Sawai, A., Le, C. H., Koutcher, J. A., Solit, D. B., Rosen, N. X., Zakowski, M. F., et al. (2007) · PLoS ONE · doi:10.1371/journal.pone.0000810 · Cited by 127
Mouse Cutaneous Melanoma Induced by Mutant BRaf Arises from Expansion and Dedifferentiation of Mature Pigmented Melanocytes
Köhler, C., Nittner, D., Rambow, F., Radaelli, E., Stanchi, F., Vandamme, N., Baggiolini, A., Sommer, L., Berx, G., van den Oord, J. J., et al. (2017) · Cell Stem Cell · doi:10.1016/j.stem.2017.08.003 · Cited by 126
Mapping the in vivo fitness landscape of lung adenocarcinoma tumor suppression in mice
Rogers, Z. N., McFarland, C. D., Winters, I. P., Seoane, J. A., Brady Jennifer, J., Yoon, S. M., Curtis, C. N., Petrov, D. A., & Winslow, M. M. (2018) · Nature Genetics · doi:10.1038/s41588-018-0083-2 · Cited by 125
The fidelity of cancer cells in PDX models: Characteristics, mechanism and clinical significance
Shi, J., Li, Y., Jia, R., & Fan, X. (2019) · International Journal of Cancer · doi:10.1002/ijc.32662 · Cited by 120
Cancer drug development: The missing links
Kunnumakkara, A. B., Bordoloi, D., Sailo, B. L., Roy, N. K., Thakur, K. K., Banik, K., Shakibaei, M., Gupta, S. C., & Aggarwal, B. B. (2019) · Experimental Biology and Medicine · doi:10.1177/1535370219839163 · Cited by 118
Activating BRAF and PIK3CA Mutations Cooperate to Promote Anaplastic Thyroid Carcinogenesis
Charles, R., Silva, J. M., Iezza, G., Phillips, W. A., & McMahon, M. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-14-0158-t · Cited by 104
Factors associated with failure of oncology drugs in late-stage clinical development: A systematic review
Jardim, D. L. F., Groves, E. S., Breitfeld, P. P., & Kurzrock, R. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.10.009 · Cited by 104
TRK Inhibition: A New Tumor-Agnostic Treatment Strategy
Kummar, S., & Lassen, U. (2018) · Targeted Oncology · doi:10.1007/s11523-018-0590-1 · Cited by 98
Self-citation
MAPK pathway in melanoma part II—secondary and adaptive resistance mechanisms to BRAF inhibition
Amaral, T. M. S., Sinnberg, T. W., Meier, F. E., Krepler, C., Levesque, M. P., Niessner, H., & Garbe, C. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2016.12.012 · Cited by 95
Modeling Tumor Immunology and Immunotherapy in Mice
Buqué, A., & Galluzzi, L. (2018) · Trends in cancer · doi:10.1016/j.trecan.2018.07.003 · Cited by 91
Genetically engineered mouse models of cancer reveal new insights about the antitumor immune response
DuPage, M. J. P., & Jacks, T. (2013) · Current Opinion in Immunology · doi:10.1016/j.coi.2013.02.005 · Cited by 90
Erlotinib resistance in mouse models of epidermal growth factor receptor-induced lung adenocarcinoma
Politi, K. A., Fan, P., Shen, R., Zakowski, M. F., & VARMUS, H. E. (2009) · Disease Models & Mechanisms · doi:10.1242/dmm.003681 · Cited by 86
RAS Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors
McCullough, A. J. (2013) · Yearbook of Pathology and Laboratory Medicine · doi:10.1016/j.ypat.2012.10.041 · Cited by 84
Relating hepatocellular carcinoma tumor samples and cell lines using gene expression data in translational research
Chen, B., Sirota, M., Fan-Minogue, H., Hadley, D., & Butte, A. J. (2015) · BMC Medical Genomics · doi:10.1186/1755-8794-8-s2-s5 · Cited by 80
Risk factors associated with having a pressure ulcer: a secondary data analysis.
Maklebust, J., & Magnan, M. A. (1994) · PubMed · Cited by 79
Roles of tumor heterogeneity in the development of drug resistance: A call for precision therapy
Wu, D., Wang, D. C., Cheng, Y., Qian, M., Zhang, M., Shen, Q., & Wang, X. (2016) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2016.11.006 · Cited by 77
Multiregion gene expression profiling reveals heterogeneity in molecular subtypes and immunotherapy response signatures in lung cancer
Lee, W.-C., Diao, L., Wang, J., Zhang, J., Roarty, E. B., Varghese, S., Chow, C.-W. B., Fujimoto, J., Behrens, C., Cascone, T., et al. (2018) · Modern Pathology · doi:10.1038/s41379-018-0029-3 · Cited by 73
The Evolutionary Landscape of Treatment for BRAFV600E Mutant Metastatic Colorectal Cancer
Mauri, G., Bonazzina, E., Amatu, A., Tosi, F., Bencardino, K., Gori, V., Massihnia, D., Cipani, T., Spina, F., Ghezzi, S., et al. (2021) · Cancers · doi:10.3390/cancers13010137 · Cited by 73
Understanding the molecular mechanisms driving metastasis
Massagué, J., Batlle, E., & Gomis, R. R. (2017) · Molecular Oncology · doi:10.1002/1878-0261.12024 · Cited by 71
Drug Sensitivity and Allele Specificity of First-Line Osimertinib Resistance EGFR Mutations
Starrett, J. H., Guernet, A. A., Cuomo, M. E., Poels, K. E., van Rosenburgh, I. K. V. A., Nagelberg, A. L., Farnsworth, D., Price, K. S., Khan, H., Ashtekar, K. D., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-3819 · Cited by 62
Kras mutant genetically engineered mouse models of human cancers are genomically heterogeneous
Chung, W., Daemen, A., Cheng, J. H., Long, J. E., Cooper, J. E., Wang, B.-E., Tran, C., Singh, M., Gnad, F., Modrusan, Z. D., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1708391114 · Cited by 61
Self-citation
Discovering and validating cancer genetic dependencies: approaches and pitfalls
Lin, A., & Sheltzer, J. M. (2020) · Nature Reviews Genetics · doi:10.1038/s41576-020-0247-7 · Cited by 59
Analysis of erythrocyte signalling pathways during Plasmodium falciparum infection identifies targets for host-directed antimalarial intervention
Adderley, J., von Freyend, S. J., Jackson, S. A., Bird, M. J., Burns, A. L., Anar, B., Metcalf, T., Semblat, J., Billker, O., Wilson, D. W., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17829-7 · Cited by 57
Genetically Engineered Mouse Models of Prostate Cancer in the Postgenomic EraPreprint
Arriaga, J. M., & Abate-Shen, C. T. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a030528 · Cited by 56
Towards quantitative and multiplexed in vivo functional cancer genomics
Winters, I. P., Murray, C. W., & Winslow, M. M. (2018) · Nature Reviews Genetics · doi:10.1038/s41576-018-0053-7 · Cited by 54
New drug approvals in oncology
Kurzrock, R., Kantarjian, H. M., Kesselheim, A. S., & Sigal, E. V. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0313-2 · Cited by 50
The landscape of BRAF transcript and protein variants in human cancer
Marranci, A., Jiang, Z., Vitiello, M., Guzzolino, E., Comelli, L., Sarti, S., Lubrano, S., Franchin, C., Echevarría-Vargas, I. M., Tuccoli, A., et al. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0645-4 · Cited by 48
Organoid modeling for cancer precision medicine
Cantrell, M. A., & Kuo, C. J. (2015) · Genome Medicine · doi:10.1186/s13073-015-0158-y · Cited by 41
Genetically Engineered Cancer Models, But Not Xenografts, Faithfully Predict Anticancer Drug Exposure in Melanoma Tumors
Combest, A. J., Roberts, P. J., Dillon, P. M., Sandison, K., Hanna, S. K., Ross, C., Habibi, S., Zamboni, B. A., Müller, M., Brunner, M., et al. (2012) · The Oncologist · doi:10.1634/theoncologist.2012-0274 · Cited by 41
The Raf Inhibitor Paradox: Unexpected Consequences of Targeted Drugs
Cox, A. D., & Der, C. J. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.02.029 · Cited by 40
Therapeutic resistance and susceptibility is shaped by cooperative multi-compartment tumor adaptation
Long, J. E., Wongchenko, M. J., Nickles, D., Chung, W., Wang, B.-E., Riegler, J., Li, J., Li, Q., Sandoval, W. N., Eastham-Anderson, J., et al. (2019) · Cell Death and Differentiation · doi:10.1038/s41418-019-0310-0 · Cited by 37
Self-citation
More than fishing for a cure: The promises and pitfalls of high throughput cancer cell line screens
Ling, A. L., Gruener, R. F., Fessler, J. L., & Huang, R. S. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.06.014 · Cited by 35
Engineering CRISPR mouse models of cancer
Weber, J., & Rad, R. (2019) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2019.04.001 · Cited by 33
Precious GEMMs: emergence of faithful models for ovarian cancer research
Stückelberger, S., & Drapkin, R. (2018) · The Journal of Pathology · doi:10.1002/path.5065 · Cited by 28
Prediction of active human dose: learnings from 20 years of Merck KGaA experience, illustrated by case studies
Peters, S. A., Petersson, C., Blaukat, A., Halle, J.-P., & Dolgos, H. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.01.002 · Cited by 28
Prolonged Response to HER2-Directed Therapy in a Patient With HER2-Amplified, Rapidly Progressive Metastatic Colorectal Cancer
Parikh, A. R., Atreya, C. E., Korn, W. M., & Venook, A. P. (2016) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0002 · Cited by 27
Stem Cells and Organoid Technology in Precision Medicine in Inflammation: Are We There Yet?
Tran, F., Klein, C., Arlt, A., Imm, S., Knappe, E., Simmons, A., Rosenstiel, P. C., & Seibler, P. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.573562 · Cited by 25
Increasing aggressiveness of patient-derived xenograft models of cervix carcinoma during serial transplantation
Wegner, C. S., Hauge, A., Andersen, L. M. K., Huang, R., Simonsen, T. G., Gaustad, J., & Rofstad, E. K. (2018) · Oncotarget · doi:10.18632/oncotarget.24783 · Cited by 20
Development of Personalized Therapeutic Strategies by Targeting Actionable Vulnerabilities in Metastatic and Chemotherapy-Resistant Breast Cancer PDXs
Punzi, S., Melixetian, M. B., Riva, L., Marocchi, F., Pruneri, G., Criscitiello, C., Orsi, F., Spaggiari, L., Casiraghi, M., Vigna, P. D., et al. (2019) · Cells · doi:10.3390/cells8060605 · Cited by 20
Transcriptional Subtypes Resolve Tumor Heterogeneity and Identify Vulnerabilities to MEK Inhibition in Lung Adenocarcinoma
Daemen, A., Cooper, J. E., Myrta, S., Wongchenko, M. J., Lin, E., Long, J. E., Foreman, O., Modrusan, Z. D., Tremayne, J. R., de la Cruz, C. C., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1835 · Cited by 20
Self-citation
Cell line-based xenograft mouse model of paediatric glioma stem cells mirrors the clinical course of the patient
Larsson, S. C., Wenger, A., Dósa, S., Sabel, M., Kling, T., & Carén, H. (2018) · Carcinogenesis · doi:10.1093/carcin/bgy091 · Cited by 18
Multiregion Genomic Analysis of Serially Transplanted Patient-derived Xenograft Tumors
Sato, K., Niida, A., Masuda, T., Shimizu, D., Tobo, T., Kuroda, Y., Eguchi, H., Nakagawa, T., Suzuki, Y., & Mimori, K. (2018) · Cancer Genomics & Proteomics · doi:10.21873/cgp.20109 · Cited by 16
Organoids as Oracles for Precision Medicine in Rectal Cancer
Kolahi, K. S., Nakano, M., & Kuo, C. J. (2020) · Cell stem cell · doi:10.1016/j.stem.2019.12.003 · Cited by 13
A Syngeneic ErbB2 Mammary Cancer Model for Preclinical Immunotherapy Trials
Pénzváltó, Z., Chen, J. Q., Tepper, C. G., Davis, R. R., Silvestrini, M. T., Umeh-Garcia, M. C., Sweeney, C. A., & Borowsky, A. D. (2019) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-019-09425-3 · Cited by 11
Insights into the FDA 2018 New Drug Approvals
Bedair, A., & Mansour, F. R. (2019) · Current Drug Discovery Technologies · doi:10.2174/1570163816666191202104315 · Cited by 9
Calcium transport by a β-diketone in model membranes
Deleers, M., Brasseur, R., & Malaisse, W. J. (1983) · Chemistry and Physics of Lipids · doi:10.1016/0009-3084(83)90003-8 · Cited by 8
Drug Sensitivity and Allele‐specificity of First‐line Osimertinib Resistance EGFR Mutations
Starrett, J. H., Guernet, A. A., Cuomo, M. E., Poels, K. E., van Rosenburgh, I. K. V. A., Nagelberg, A. L., Farnsworth, D., Price, K. S., Khan, H., Ashtekar, K. D., et al. (2020) · The FASEB Journal · doi:10.1096/fasebj.2020.34.s1.00612 · Cited by 7
EGFR-Mediated Re-Activation of MAPK Signaling Contributes to Insensitivity of BRAF Mutant Colorectal Cancers to RAF Inhibition
Ebi, H. (2012) · Annals of Oncology · doi:10.1016/s0923-7534(20)32033-0 · Cited by 6
[The effects of extracts of malignant neoplasms on immunologic reactions].
Na, S., SAVCHUK, O. E., & Tf, K. (1968) · PubMed · Cited by 5
Abstract 1697: Humanized immune-oncology mouse models
Stecklum, M., Wulf-Goldenberg, A., Brzezicha, B., Fichtner, I., & Hoffmann, J. (2017) · Cancer Research · doi:10.1158/1538-7445.am2017-1697 · Cited by 3
Patient-Derived Xenograft (PDX) Models: An Emerging Platform for Cancer Drug Development and Translational Research
Murphy, J. F. (2016) · MOJ Immunology · doi:10.15406/moji.2016.03.00094 · Cited by 2
Predicting tumor-immune response to checkpoint inhibitors using a novel patient-derived live tumor explant model.
Radhakrishnan, P., Goldman, A. J., Ulaganathan, B., Kumar, A. T., Maciejko, L., Gertje, H. P., Shanthappa, B., Mehrotra, D. G., Biswas, M., Thiyagarajan, S., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.e20035 · Cited by 2
[Differentiation of Bordetella bronchiseptica strains. 3. Brief study of different reaction of various mouse lines to Bordetella bronchiseptica strains].
Hoffmann, A., Krüger, M., & Horsch, F. (1984) · PubMed · Cited by 1
[Health policy--dangerous to be alive].
Fasting, U. (1994) · PubMed · Cited by 1
Melanoma Model Systems
Schittek, B., de Jel, M. M., & Tüting, T. (2017) · Springer eBooks · doi:10.1007/978-3-319-41319-8_15 · Cited by 1

Research works printed but not linked: 2

Lightfoot, J. T., Bamman, M. M. & Booth, F. W. Translation goes both ways: the power of reverse translation from human trials into animal models. Transl. J. Am. Coll. Sports Med. 2, 29–31 (2017).
Jarnuczak, A. F. et al. An integrated landscape of protein expression in human cancer. Preprint at biorxiv https://doi.org/10.1101/665968v1.abstract (2019). · DOI

Sorted by citations

Organoids
Zhao, Z., Chen, X., Dowbaj, A. M., Sljukic, A., Bratlie, K., Lin, L., Fong, E. L. S., Balachander, G. M., Chen, Z., Soragni, A., et al. (2022) · Nature Reviews Methods Primers · doi:10.1038/s43586-022-00174-y · Cited by 1,082
Patient-derived xenograft models in cancer therapy: technologies and applications
Liu, Y., Wu, W., Cai, C., Zhang, H., Shen, H., & Han, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01419-2 · Cited by 533
Drug resistance in cancer: molecular mechanisms and emerging treatment strategies
Li, J., Hu, J., Yang, Y., Zhang, H., Liu, Y., Fang, Y., Qu, L., Lin, A., Luo, P., Jiang, A., et al. (2025) · Molecular Biomedicine · doi:10.1186/s43556-025-00352-w · Cited by 120
Coding, or non-coding, that is the question
Poliseno, L., Lanza, M., & Pandolfi, P. P. (2024) · Cell Research · doi:10.1038/s41422-024-00975-8 · Cited by 101
Personalized chordoma organoids for drug discovery studies
Al Shihabi, A., Davarifar, A., Nguyen, H. T. L., Tavanaie, N., Nelson, S. D., Yanagawa, J., Federman, N., Bernthal, N., Hornicek, F., & Soragni, A. (2022) · Science Advances · doi:10.1126/sciadv.abl3674 · Cited by 75

See all 121

Authors: Honkala, A., Malhotra, S. V., Kummar, S., & Junttila, M. R.
Affiliations: Oregon Health & Science University (US)
ORIC Pharmaceuticals, Inc. (United States) (US)
Corresponding author: Kummar, Shivaani
Junttila, Melissa R.
ORCID: Honkala, Alexander
Malhotra, Sanjay V.
Kummar, Shivaani
Junttila, Melissa R.
Venue: Nature Reviews Drug Discovery
Publisher: Springer Science and Business Media LLC
Published: 2021-10-26
Volume: 21
Issue: 2
Pages: 99-114
ISSN: 1474-1776 (ISSN-L)
1474-1784
DOI: 10.1038/s41573-021-00301-6
OpenAlex: W3210942885
Cited by: 121
References: 166
Citations by year: 2026: 30 · 2025: 31 · 2024: 20 · 2023: 23 · 2022: 16 · 2021: 1
FWCI: 2.97
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
www.springer.com/tdm (vor)
Locations: Nature Reviews Drug Discovery (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Veterinary › Small Animals › Animal testing and alternatives
Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Science, Research, and Medicine
Keywords: anticancer drug development, preclinical models, prediction model, translational research, forward translation, reverse translation, molecularly targeted cancer therapy, drug attrition, tumor biology
MeSH terms: Drug Development, Animals, Antineoplastic Agents, Drug Evaluation, Preclinical, Humans, Neoplasms, Biomarkers, Tumor, Molecular Targeted Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Harnessing the predictive power of preclinical models for oncology drug development

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks